[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

$rapp

Rapport Therapeutics ($rapp) shares are surging following positive trial results and an upgrade to "buy" by Goldman Sachs. A director's purchase of shares further boosts investor confidence.

About $rapp

News and analysis related to Rapport Therapeutics ($rapp), a biopharmaceutical company.

Insights #

$rapp sentiment is up XXX% from the previous week.

Engagements: XXX #

Engagements Line Chart
Engagements 24-Hour Time-Series Raw Data
Current Value: XXX
Daily Average: XXXXX
1 Week: XXXXX -XX%
1 Month: XXXXXX -XX%
1-Year High: XXXXXXX on 2025-09-08
1-Year Low: X on 2025-05-26

Social Network	X
Engagements	XXX

Mentions: XX #

Mentions Line Chart
Mentions 24-Hour Time-Series Raw Data
Current Value: XX
Daily Average: XX
1 Month: XX +105%
1-Year High: XXX on 2025-09-10
1-Year Low: X on 2025-05-24

Social Network	X
Mentions	XX

Creators: X #

Creators Line Chart
Creators 24-Hour Time-Series Raw Data
X unique social accounts have posts mentioning $rapp in the last XX hours which is up XX% from X in the previous XX hours Daily Average: XX
1 Month: XX +92%
1-Year High: XXX on 2025-09-08
1-Year Low: X on 2025-05-24

The most influential creators that mention $rapp in the last XX hours

Creator	Rank	Followers	Posts	Engagements
@BiopharmIQ	X	XXXXXX	X	X

Sentiment: XXX% #

Sentiment Line Chart
Sentiment 24-Hour Time-Series Raw Data
Current Value: XXX%
Daily Average: XX%
1 Week: XXX% +50%
1 Month: XXX% no change
1-Year High: XXX% on 2025-05-19
1-Year Low: XX% on 2025-10-08

Most Supportive Themes

Positive Clinical Trial Results: (60%) RAP-219 Phase 2a trial data showed significant seizure reduction and seizure freedom in some patients.
Analyst Upgrades and Price Targets: (25%) Goldman Sachs upgraded the stock to "buy" and set a price target.
Insider Buying: (15%) A director's purchase of $XXX million worth of shares signals confidence.

Most Critical Themes

Network engagement breakdown: (1%) X has XX% positive, XX% neutral, and X% negative sentiment.

Network engagement breakdown:

Network	Positive	%	Neutral	%	Negative	%
X	XX	X%	XXX	XX%	X	X%

Total	XX	X%	XXX	XX%	X	X%

Top assets mentioned In the posts about $rapp in the last XX hours

Landwolf (WOLF) Semtech Corp (SMTC) Tourmaline Bio, Inc. Common Stock (TRML) Summit Therapeutics Inc. Common Stock (SMMT) Dyne Therapeutics, Inc. Common Stock (DYN) Dyne Therapeutics, Inc. Common Stock (DYN) BridgeBio Pharma, Inc. Common Stock (BBIO) United Community Banks, Inc. (UCB) Neurocrine Biosciences, Inc. (NBIX) Neurocrine Biosciences, Inc. (NBIX)

Top topics mentioned In the posts about $rapp in the last XX hours

stocks healthcare, $wolf, $smtc, stocks crypto treasuries, $vor, $trml, $smmt, stocks technology, $atxs, dyne therapeutics, $dyn, $elvn, $bbio, $ucb, neurocrine biosciences inc, $nbix, brad, $bkkt, $fly, coins arbitrum, $anab, $idt, runner, $bnai, $gipr, $dfli, $eras, $telo, $xlo, $txg, $ctxr, novartis, $novnsw, $orcl, $crdo, $qbts, $leu, $ag, $air, $alm, $ampx, $apld, stocks consumer cyclical, $sats, alibaba group, coins defi, make a, $stec, $gp, coins algorand, stocks, $hive, monolithic power systems inc, $sonm, $qqq, $tblt, $spcb, stocks bitcoin treasuries, stocks energy, $mnkd, $gri, $gctk, $aqms, $pepg, $mlys, $kron, $ipsc, $abvx, $ctnm, $frpt, $swx, sec, $lab